(MENAFN- EIN Presswire) EINPresswire/ -- Goody PR agency is honored to receive two top 2025 MarCom Awards – Platinum level for two categories: 1. Best Public Relations Program and 2. Best Publicity ...

I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Vir Biotechnology (VIR). The reason why I want to go over this biotech next is because it is ...

Firefly Aerospace Inc. (NASDAQ:FLY) Q2 2025 Earnings Call Transcript September 23, 2025 Operator: Greetings. Welcome to the Firefly Aerospace Second Quarter 2025 Financial Results Conference Call.

Community driven content discussing all aspects of software development from DevOps to design patterns. One of the first things a developer will be told after they join a new software project is to ...

ECLIPSE registrational program now fully underway, following enrollment of the first patient in ECLIPSE 3 ECLIPSE 3 is designed to compare the combination of tobevibart and elebsiran to bulevirtide in ...

First patient enrolled in ECLIPSE 2 Phase 3 clinical trial evaluating the switch to the combination of tobevibart and elebsiran in patients not achieving undetectable hepatitis delta virus RNA despite ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial, which is designed to compare the ...

(RTTNews) - Northrop Grumman Corp. (NOC), Thursday announced that it has committed $50 million to Firefly Aerospace to accelerate production of their jointly developed medium class launch vehicle, ...

CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...

First patient enrolled in ECLIPSE 1 Phase 3 clinical trial evaluating combination of tobevibart and elebsiran for chronic suppressive treatment ECLIPSE program designed to enable regulatory ...